Mission-driven impact Target fundraising and grant alignment opportunities by presenting EE as a catalyst for rare CF subpopulation research, focusing on the final 10% underserved group and potential partnerships with biotech firms seeking novel gene therapies.

Clinical trial access Leverage EE's CF Clinical Trial Connect platform to offer partnerships with CROs, trial sites, and patient recruitment services, highlighting the ability to accelerate enrollment for underserved CF patient cohorts.

Strategic partnerships Position EE as a bridge between researchers, pharma sponsors, and patient communities; propose collaboration models for co-funding, data sharing, and accelerated translational research for niche CF mutations.

Thought leadership Engage EE’s Scientific Advisory Board network and patient registry to create paid advisory or consultant opportunities, along with sponsored expert webinars and whitepapers targeting CF mutation groups and rare disease researchers.

Sustainability leverage Align with EE’s mission to scale impact through grants and a legacy of research acceleration; offer multi-year funding programs, impact reporting, and ESG-aligned partnerships appealing to foundations and impact investors.